Clinical trial
A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients…
NCT00297362 · Janssen Cilag Pharmaceutica S.A.C.I., Greece, Industry · Completed
Key facts
| NCT number | NCT00297362 |
|---|---|
| Title | A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's Disease |
| Official title | Open Observational Study of Galantamine Hydrobromide Administration for the Treatment of Patients With Mild to Moderate Dementia of the Alzheimer Type |
| Lead sponsor | Janssen Cilag Pharmaceutica S.A.C.I., Greece, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | Alzheimer Disease |
| Intervention type | Drug |
| Interventions | Galantamine hydrobromide |
| Enrollment | 344 |
| Start date | Jun 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Feb 28, 2006 |
| Last update posted | Mar 26, 2012 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: